Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
18.62
+0.85 (4.78%)
Nov 5, 2024, 4:00 PM EST - Market closed

Entrada Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Net Income
54.95-6.69-94.62-51.16-26.52-5.1
Depreciation & Amortization
3.522.841.91.120.330.1
Loss (Gain) From Sale of Assets
---0.070.02-
Loss (Gain) From Sale of Investments
-9.51-5.780.15---
Stock-Based Compensation
17.0613.119.92.530.330.29
Other Operating Activities
------6.27
Change in Accounts Receivable
2.42-5.88----
Change in Accounts Payable
0.55-2.815.29-0.720.630.37
Change in Unearned Revenue
-105.06139.98----
Change in Income Taxes
2.254.02----
Change in Other Net Operating Assets
19.861-16.4-2.71-0.35-0.19
Operating Cash Flow
-13.97139.8-93.79-50.86-25.57-10.8
Capital Expenditures
-3.5-5.61-2.89-4.58-2.32-0.63
Investment in Securities
-58.62-132.78-145.76---
Investing Cash Flow
-62.12-138.4-148.65-4.58-2.32-0.63
Issuance of Common Stock
102.2521.040.48191.630.250.04
Financing Cash Flow
102.2521.040.48307.4650.090.04
Net Cash Flow
26.1722.45-241.96252.0222.2-11.39
Free Cash Flow
-17.46134.19-96.67-55.44-27.89-11.43
Free Cash Flow Margin
-8.11%104.01%----
Free Cash Flow Per Share
-0.494.06-3.09-8.85-25.23-12.25
Cash Income Tax Paid
14.7214.72----
Levered Free Cash Flow
-33.21149.04-58.56-36.26-17.21-
Unlevered Free Cash Flow
-33.21149.04-58.56-36.26-17.21-
Change in Net Working Capital
82.45-140.686.683.37-1.13-
Source: S&P Capital IQ. Standard template. Financial Sources.